Literature DB >> 23881925

Protein kinase C-δ-mediated recycling of active KIT in colon cancer.

Misun Park1, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim.   

Abstract

PURPOSE: Abnormal signaling through receptor tyrosine kinase (RTK) moieties is important in tumorigenesis and drug targeting of colorectal cancers. Wild-type KIT (WT-KIT), a RTK that is activated upon binding with stem cell factor (SCF), is highly expressed in some colon cancers; however, little is known about the functional role of SCF-dependent KIT activation in colon cancer pathogenesis. We aimed to elucidate the conditions and roles of WT-KIT activation in colon cancer tumorigenesis. EXPERIMENTAL
DESIGN: Colorectal cancers with KIT expression were characterized by immunoblotting and immunohistochemistry. The biologic alterations after KIT-SCF binding were analyzed with or without protein kinase C (PKC) activation.
RESULTS: We found that WT-KIT was expressed in a subset of colon cancer cell lines and was activated by SCF, leading to activation of downstream AKT and extracellular signal-regulated kinase (ERK) signaling pathways. We also showed that KIT expression gradually decreased, after prolonged SCF stimulation, due to lysosomal degradation. Degradation of WT-KIT after SCF binding was significantly rescued when PKC was activated. We also showed the involvement of activated PKC-δ in the recycling of WT-KIT. We further showed that a subset of colorectal cancers exhibit expressions of both WT-KIT and activated PKC-δ and that expression of KIT is correlated with poor patient survival (P = 0.004).
CONCLUSIONS: Continuous downstream signal activation after KIT-SCF binding is accomplished through PKC-δ-mediated recycling of KIT. This sustained KIT activation may contribute to tumor progression in a subset of colon cancers with KIT expression and might provide the rationale for a therapeutic approach targeting KIT. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881925     DOI: 10.1158/1078-0432.CCR-13-0131

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

Review 1.  Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases.

Authors:  Hung Nguyen; David Aum; Sherwin Mashkouri; Gautam Rao; Juan Diego Vega Gonzales-Portillo; Stephanny Reyes; Cesario V Borlongan
Journal:  Expert Rev Neurother       Date:  2016-05-13       Impact factor: 4.618

Review 2.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

3.  Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

Authors:  Rui-Hua Xu; Lin Shen; Ke-Ming Wang; Gang Wu; Chun-Mei Shi; Ke-Feng Ding; Li-Zhu Lin; Jin-Wan Wang; Jian-Ping Xiong; Chang-Ping Wu; Jin Li; Yun-Peng Liu; Dong Wang; Yi Ba; Jue-Ping Feng; Yu-Xian Bai; Jing-Wang Bi; Li-Wen Ma; Jian Lei; Qing Yang; Hao Yu
Journal:  Chin J Cancer       Date:  2017-12-22

4.  Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.

Authors:  A M Ohm; A-C Tan; L E Heasley; M E Reyland
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

5.  Phosphorylation of PKCδ by FER tips the balance from EGFR degradation to recycling.

Authors:  Ana Lonic; Freya Gehling; Leila Belle; Xiaochun Li; Nicole L Schieber; Elizabeth V Nguyen; Gregory J Goodall; Robert G Parton; Roger J Daly; Yeesim Khew-Goodall
Journal:  J Cell Biol       Date:  2021-02-01       Impact factor: 10.539

6.  B7-H4 expression is upregulated by PKCδ activation and contributes to PKCδ-induced cell motility in colorectal cancer.

Authors:  Bin Zhou; Youwei Lu; Zhiming Zhao; Tongguo Shi; Hongya Wu; Weichang Chen; Liang Zhang; Xueguang Zhang
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.